Jasper Therapeutics, Inc. · NASDAQ:JSPR

Jasper Therapeutics — Amplitude Healthcare Acquisition — SPAC Merger (September 2021)

33 slides from Jasper Therapeutics's SPAC merger presentation, Sep 9, 2021

  1. Slide 1: Enabling Cures with Hematopoietic Stem Cell Transplants

    Enabling Cures with Hematopoietic Stem Cell Transplants September 2021

  2. Slide 2: Safe Harbor Statement

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Safe Harbor Statement 2 About this Presentation This investor presentation (this “Presentation”) is for informational purposes only to assist interested parties in making th eir own evaluation wit

  3. Slide 3: Jasper Highlights

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Jasper Highlights 3 Novel hematopoietic stem cell engineering platform to expand the curative potential of allogeneic and autologous cellular therapy, in vivo POC in 2021 and potential IND in 2022

  4. Slide 4: World Class Management Team, Scientific Advisory Board and Investors

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Harry Malech , Chief Genetic Immunotherapy Section NIAID Jeff Ravetch , Professor of Molecular Genetics and Immunology Arthur Weiss , Prof Medicine, Microbiology and Immunology; HHMI Investigator

  5. Slide 5: Addressing Major Limitations of Hematopoietic Cell Transplant by Targeting the Stem Cell

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Addressing Major Limitations of Hematopoietic Cell Transplant, Improving Conditioning and Donor Grafts by Targeting the Stem Cell 5 JSP191 Stroma Cells Stroma Cells Stroma Cells JSP191 Blocks SCF

  6. Slide 6: Jasper's Expanding Pipeline

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Jasper’s Expanding Pipeline 6 INDICATION RESEARCH PRECLINICAL CLINICAL R&D SPONSOR JSP191 CONDITIONING AML/MDS SCID Autoimmune (Lupus, Scleroderma, MS) Fanconi Anemia Sickle Cell Disease Chronic G

  7. Slide 7: Jasper's Success Can Lead to Routine Stem Cell Transplants

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Jasper’s Success Can Lead to Routine Stem Cell Transplants to Potentially Cure Hundreds of Thousands of Patients 7 > 20,000 > 80,000 JSP191 > 200,000 JSP191 + Jasper eHSC • Jasper engineering to f

  8. Slide 8: Unmet Medical Need: Reducing Toxicities and Transplant Related Mortality

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Unmet Medical Need: Reducing Toxicities and Transplant Related Mortality to Expand Use of Gene Therapies and Hematopoietic Stem Cell Transplant 8 [1] Ramasamy K, Lim ZY, Paglicua A, et al. Bone Ma

  9. Slide 9: JSP191 Uniquely Blocks Stem Cell Factor Receptor (CD117) Signaling

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191 Uniquely Blocks Stem Cell Factor Receptor (CD117) Signaling Leading to Stem Cell Depletion without Significant Off - Target Toxicities 9 SCF / CD117 interaction required for stem cell survi

  10. Slide 10: JSP191 Validated in Multiple Disease Models

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191 Validated in Multiple Disease Models Where HSC is Standard Curative Therapy 10 Demonstrated robust pre - clinical data in multiple models of transplant and disease • Disease: SCID, AML, MDS

  11. Slide 11: JSP191's Single Agent Clinical POC in SCID

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191’s Single Agent Clinical POC in Ultra Orphan Indication, Severe Combined Immunodeficiency (SCID) SCID is a lethal genetic immune disorder. HCT is the only proven cure; without it most infant

  12. Slide 12: JSP191 Conditioning in SCID Clinical Studies to Date

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191 Conditioning in SCID Clinical Studies to Date Demonstrates Durable Naive T - cell Production and Immune System Reconstitution 12 *Expected Level for Clinical Benefit No Conditioning (Matche

  13. Slide 13: JSP191 MDS/AML Dose Finding (n=6)

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191 MDS/AML Dose Finding (n=6): MRD Positive Transplant Patients Not Eligible for Full Myeloablative Conditioning 13 ClinicalTrials.gov NCT04429191 MRD positive MDS/AML patients (n=6) n ot elig

  14. Slide 14: JSP191 MDS/AML: Safety

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191 MDS/AML: Safety 14 JSP191 with 200 cGy TBI plus 30 mg/m 2 x 3 days fludarabine Patient ages 65 - 74 yrs 3 AML + 3 MDS patients • Protocol allows for outpatient conditioning • No infusion re

  15. Slide 15: JSP191 MDS/AML: 100% Donor Cell Engraftment

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191 MDS/AML: 100% Donor Cell Engraftment with >95% Myeloid Chimerism in Six of Six Patients 15 Percent Myeloid Chimerism 90 days post - Transplant Absolute Neutrophil Count (k/ uL ) 0 10 20 30

  16. Slide 16: JSP191 Conditioning Leads to Successful Transplant and MRD Reduction

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191 Conditioning Leads to Successful Transplant and Conversion to MRD - Negative/ MRD Reduction in All Evaluable Subjects 16 Subject Screening TD+28 TD+90 TD+180 NGS, Flow, or Cyto NGS, Flow, o

  17. Slide 17: JSP191 MDS/AML Dose Expansion (Ongoing)

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191 MDS/AML Dose Expansion (Ongoing): Study in MDS/AML patients in CR Plus Expansion to MDS or AML Patients With Active Disease (n=24) 17 MRD Positive MDS/AML Patients Not Eligible for Standard

  18. Slide 18: JSP191 MDS/AML Potential Paths to Regulatory Approvals

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191 MDS/AML Potential Paths to Regulatory Approvals 18 Randomized 2 - arm (n ~ 250) Trial could open in 2022 MDS/AML Patients in Morphologic CR (<5% Blasts) undergoing a matched allogenic HCT n

  19. Slide 19: Allogenic Transplant in Refractory Autoimmune Disease

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Allogenic Transplant in Refractory Autoimmune Disease Establishes a New Immune Repertoire Leading to Reestablished Self Tolerance 19 New Immune Repertoire Reestablishes Self Tolerance Central Tole

  20. Slide 20: JSP191 Autoimmune Studies

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191 Autoimmune Studies: Evaluation of JSP191 For Patients with Severe Autoimmune Diseases 20 JSP191 in combination with a reduced intensity conditioning regimen for allo - HCT SAFETY RUN - IN D

  21. Slide 21: Outpatient JSP191 May Save Hospitals ~9 Days of Pre-Transplant Stay

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication In Addition to Enabling Cures, Outpatient JSP191 May Save Hospitals ~9 Days of Pre - Transplant Stay and Increase DRG Profitability Patient Transplant Journey (Days)* - 9 - 8 - 7 - 6 - 5 - 4 - 3 -

  22. Slide 22: eHSCs Potential to Change Allogeneic and Gene Therapy Transplant

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication eHSCs Potential to Change to Allogeneic and Gene Therapy Transplant 22 eHSC Removes need for donor immune cells , eliminating risk of GVHD Reduces / eliminates need for toxic conditioning Improves

  23. Slide 23: Proof of Concept: JSP502 Engineered HSCs

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Proof of Concept: JSP502 Engineered HSCs Can Proliferate Independent of Stem Cell Factor And Can Be Given Together With JSP191 Conditioning In - Vitro 23 0.00 0.05 0.10 0.15 1000 10 0.1 100 1 SCF

  24. Slide 24: Proof of Concept: JSP705 Increases CXCR4 Expression

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Proof of Concept: JSP705 Can Increase CXCR4 Surface Protein Expression in Human CD34+ Cells 24 JSP705 mRNA in CD34+ Cells mRNA Insertion Jasper mRNA inserted into CD34+ cells via electroporation S

  25. Slide 25: JSP191 and eHSCs May Expand the Eligible Patient Population

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication JSP191 and eHSCs May Significantly Expand the Eligible Patient Population for Curative Stem Cell Transplants 25 Allo - HCT for Heme Malignancies Allo - HCT for Non - Malignant Disease Autologous G

  26. Slide 26: Jasper Target Milestones

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Jasper Target Milestones 26 x Q2 2021 – JSP191 AML/MDS Phase 1a top line 90 - day data x Q2 2021 – JSP191 AML/MDS open enrollment of Phase 1b expansion • Q4 2021 – JSP191 Autoimmune IND filing for

  27. Slide 27: Appendix

    THERAPEUTICS INC APPENDIX

  28. Slide 28: PIPE Overview

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication PIPE Overview 28 Type of offering Private Investment in Public Equity (PIPE) Target Company Jasper Therapeutics, Inc. SPAC sponsor Amplitude Healthcare Acquisition Corp. Size of offering $100mm Pr

  29. Slide 29: Jasper and Amplitude Add Significant Capital

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Jasper and Amplitude Add Significant Capital to Advance a Formidable Leader in Hematopoietic Stem Cell Transplant for a Range of Indications Creating well funded leader in hematopoietic stem cells

  30. Slide 30: Risk Factors

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Risk Factors 30 The list below of risk factors has been prepared solely for purposes of the proposed private placement transaction (the “Priv ate Placement”) as part of the proposed business combi

  31. Slide 31: Risk Factors (cont'd)

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Risk Factors (cont’d) 31 Risks Related to the Regulatory Regime for Jasper’s Product Candidates Jasper has no experience as a company in obtaining regulatory approval for a drug. The regulatory la

  32. Slide 32: Risk Factors (cont'd)

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Risk Factors (cont’d) 32 Risks Related to Jasper’s Intellectual Property Jasper’s commercial success depends on its ability to obtain, maintain and protect its intellectual property and proprietar

  33. Slide 33: Risk Factors (cont'd)

    © 2021 Jasper Therapeutics, Inc. JSP191 is an investigative drug and is not approved for any indication Risk Factors (cont’d) 33 Risks Related to the Private Placement AMHC may be unable to raise sufficient capital in the Private Placement or otherwise obtain additional financing to complete the Bus

Amplitude Healthcare Acquisition — SPAC Merger (September 2021) on 6ix